课题基金 / 基金详情

Fine-tuning of Hematopoiesis by the Mirn23a/b MiRNA Clusters

Fine-tuning of Hematopoiesis by the Mirn23a/b MiRNA Clusters
Mirn23a/b miRNA 簇对造血作用的微调
批准号:
9518884
负责人:
RICHARD E DAHL
金额:
$28.35万
依托单位国家:
美国
项目类别:
财政年份:
2016
资助国家:
美国
项目状态:
已结题
起止时间:
2016-06-01 至 2020-05-31

项目摘要

项目成果

相似基金

相关文献

中文摘要
翻译
 描述(申请人提供):获得性血细胞减少症是一种或多种血细胞类型显著减少的血液疾病。了解造血干细胞和祖细胞(HSPC)的发育对于开发新的细胞减少治疗方法至关重要。信号转导途径和转录因子网络协调造血。然而,使这些促进血液发育的途径痛苦伴随着促进血液系统恶性肿瘤的风险。MiRNAs被描述为基因表达的微调因子,因为它们通常下调目标基因不到50%。我们假设,通过靶向信号或转录网络中的多个基因,miRNAs对细胞分化有重要影响。然而,我们推测,由于对单个靶点的影响不大,调节miRNA表达将降低促进恶性肿瘤的风险。利用过表达和shRNA实验,我们已经发表了miRNA簇mirn23a,它编码3个前miRNAs,调节造血祖细胞对免疫细胞命运的指定,以及从胚胎干细胞到HSPC的发育。为了进一步研究miRNA对造血的调控,我们产生了mirn23a-/-小鼠。这些小鼠由于同源mirn23b基因的补偿而存活;然而,mirn23a/b miRNAs的低形态表达导致B细胞增加,骨髓和脾中单核细胞/粒细胞减少。免疫细胞群体的这些变化似乎是由于对骨髓祖细胞群体的影响。初步证据表明,mirn23a/b miRNAs影响淋系和髓系祖细胞上游多潜能祖细胞(MPP)中转录因子的表达。Mirn23a调节PI3K/Akt通路和BMP/Smad通路,有可能影响造血祖细胞转录因子的平衡。在这个项目中,我们将检测缺乏mirn23a和mirn23b基因的小鼠的造血功能。我们假设mirn23a/b miRNAs作为细胞信号通路的变阻器,控制成年HSPC的发育和功能。该项目的完成将确定mirn23a/b miRNAs在成人HSPC发生和维持中的作用,并确定mirn23a/b表达是否是一种新的机制,在造血过程中协调PI3K/Akt和BMP/Smad的活性。重要的是,结果将证明mirn23a/b miRNAs是否是造血分化的调节者,可以作为细胞减少症治疗的靶点。与目前的细胞因子疗法或使用细胞因子模拟物相比,靶向miRNAs可能具有较低的促进恶性肿瘤的风险。打破细胞因子刺激的标准方法可能是治疗细胞减少症问题的一种创新方法,这将比频繁的静脉注射细胞因子更方便,并降低有害副作用的风险。
英文摘要
 DESCRIPTION (provided by applicant): Acquired cytopenias are blood disorders in which one or more blood cell types are greatly reduced. Understanding hematopoietic stem and progenitor cell (HSPC) development is critical for the development of new cytopenia treatments. Signal transduction pathways and networks of transcription factors orchestrate hematopoiesis. However, agonizing these pathways to increase blood development comes with the risk of promoting hematological malignancies. MiRNAs have been described as fine-tuners of gene expression as they typically downregulate their targets by less than 50%. We hypothesize that through targeting multiple genes in a signaling or transcriptional network miRNAs have major effects on cell differentiation. However we postulate that modulating miRNA expression will carry lower risk of promoting malignancy due to their modest effects on individual targets. Using overexpression and shRNA experiments, we have published that the miRNA cluster mirn23a, which codes for 3 pre-miRNAs, regulates specification of hematopoietic progenitors to immune cell fates, as well as the development of HSPCs from embryonic stem cells. To further investigate miRNA regulation of hematopoiesis, we generated mirn23a-/- mice. These mice are viable due to compensation from the homologous mirn23b gene; however, the hypomorphic expression of mirn23a/b miRNAs results in increased B cells, and decreased monocytes/granulocytes in the bone marrow and spleen. These changes in immune cell populations appear to be due to effects on bone marrow progenitor populations. Preliminary evidence suggests that mirn23a/b miRNAs affect transcription factor expression in the multipotential progenitor (MPP) upstream of lymphoid and myeloid progenitors. Mirn23a modulates both the PI3K/ Akt pathway, and BMP/ Smad pathways, which has the potential to influence the balance of transcription factors in hematopoietic progenitors. In this project we wil examine hematopoiesis in mice lacking both the mirn23a, and mirn23b genes. We hypothesize that the mirn23a/b miRNAs act as a rheostat for cell signaling pathways, which control the development and function of adult HSPCs. The completion of this project will define the role of the mirn23a/b miRNAs in adult HSPC development and maintenance, as well as determine whether mirn23a/b expression is a novel mechanism for coordinating PI3K/ Akt, and BMP/ Smad activity during hematopoiesis. Importantly results will demonstrate whether the mirn23a/b miRNAs are regulators of hematopoietic differentiation that could be pursued as targets for cytopenia therapy. Targeting miRNAs may carry less risk of promoting malignancies than current cytokine regimens or use of cytokine mimetics. Breaking away from the standard approach of cytokine stimulation could be an innovative approach to the problem of treating cytopenias, which would be more convenient than frequent intravenous cytokine injections, and have reduced risk of harmful side effects.
期刊论文(2)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1016/j.exphem.2017.12.007
发表时间: 2018-03
期刊: Experimental hematology
影响因子: 2.6
作者: [Kurkewich JL, Boucher A, Klopfenstein N, Baskar R, Kapur R, Dahl R]
通讯作者: Dahl R
DOI: 10.1371/journal.pgen.1006887
发表时间: 2017-07
期刊: PLoS genetics
影响因子: 4.5
作者: [Kurkewich JL, Hansen J, Klopfenstein N, Zhang H, Wood C, Boucher A, Hickman J, Muench DE, Grimes HL, Dahl R]
通讯作者: Dahl R
海外基金